Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Reese Pharmaceutical Company
WARNING LETTER
•Reese Pharmaceutical Company•November 24, 2010

Reese Pharmaceutical Company – FDA Warning Letter, Nov 24, 2010

Record Details

This FDA Warning Letter (CIN-11-160272-16) was issued to Reese Pharmaceutical Company following a November 3-24, 2010 inspection, identifying significant Current Good Manufacturing Practice (CGMP) violations for Finished Pharmaceuticals (21 CFR Parts 210 and 211). These violations render drug products adulterated under 21 U.S.C. § 351(a)(2)(B). The firm's December 10, 2010 response was deemed inadequate.

Key violations include: 1. **Inadequate Investigations (21 CFR § 211.192):** Failure to thoroughly investigate a mislabeling incident where cold decongestant tablets were labeled as cough expectorant (Lot 091612). The firm failed to identify a root cause, provide rationale for the expectorant product not being at risk, and define an "unaccounted" category in reconciliation. Employee training on revised SOPs "A11-Inspection of Finished Product" and "A16-Custom Imprint Tracking Form" was also not addressed. 2. **Lack of Labeling Control (21 CFR § 211.125(a)):** Issuing various labels weeks in advance and storing them in uncontrolled open boxes, increasing mix-up risk. The firm's proposed tracking form was

Company
Reese Pharmaceutical Company
Inspection date
November 24, 2010
Product type
Drugs
Office
Cincinnati District Office
Person
  • Teresa C. Thompson
View Company Profile

ID · 2316d10f-05d7-4ab3-ab33-c330fe56f0e1

Violation Codes3
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Reese Pharmaceutical Company
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.